Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study

Naheema S Gordon; Laura A Baxter; Anshita Goel; Roland Arnold; Baljit Kaur; Wenyu Liu; Sarah J Pirrie; Syed Hussain; Richard Viney; Daniel Ford; Anjali Zarkar; Mary A Wood; Timur Mitin; Reid F Thompson; Nicholas D James; Douglas G Ward; Richard T Bryan

doi:10.1111/bju.15589

Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study

Naheema S Gordon
, Laura A Baxter
, Anshita Goel
, Roland Arnold
, Baljit Kaur
, Wenyu Liu
, Sarah J Pirrie
, Syed Hussain
, Richard Viney
, Daniel Ford
, Anjali Zarkar
, Mary A Wood
, Timur Mitin
, Reid F Thompson
, Nicholas D James
, Douglas G Ward
, Richard T Bryan

Research output: Contribution to journal › Article › peer-review

224 Downloads (Pure)

Original language	English
Pages (from-to)	32-34
Number of pages	3
Journal	BJU International
Volume	129
Issue number	1
Early online date	7 Sept 2021
DOIs	https://doi.org/10.1111/bju.15589
Publication status	Published - 1 Jan 2022

Bibliographical note

Funding Information:
The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee – CRUK‐OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd.

Funding Information:
Timur Mitin: UpToDate, Inc (royalties for chapter authorship), Novocure (study grant and advisory board), AstraZeneca (advisory board). Richard T. Bryan: Olympus Medical Systems (advisory board), Janssen (advisory board), UroGen Pharma (research grant), QED Therapeutics (research grant), Nonacus Limited (advisory board). Douglas G. Ward: Nonacus Limited (advisory board).

Funding Information:
The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee ? CRUK-OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd. The authors thank Katie Marquis, Florence Pethick and Giorgio Pea from Thermo Fisher UK, Nonacus Limited, and West Midlands Regional Genetics Laboratory. The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee ? CRUK-OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd.

Funding Information:
The authors thank Katie Marquis, Florence Pethick and Giorgio Pea from Thermo Fisher UK, Nonacus Limited, and West Midlands Regional Genetics Laboratory. The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee – CRUK‐OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Urology
Cetuximab/administration & dosage
Liquid Biopsy
Neoplasm Invasiveness
Humans
Treatment Outcome
Tumor Suppressor Protein p53/genetics
Neoplasm Recurrence, Local/genetics
Chemoradiotherapy
Sequence Analysis, DNA
Mitomycin/administration & dosage
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Pilot Projects
Urinary Bladder Neoplasms/genetics
DNA, Neoplasm/analysis
Fluorouracil/administration & dosage
Muscle, Smooth/pathology
Mutation
Receptor, Fibroblast Growth Factor, Type 3/genetics
Clinical Trials, Phase I as Topic
Biomarkers, Tumor/urine
Clinical Trials, Phase II as Topic
Telomerase/genetics

Access to Document

10.1111/bju.15589Licence: Creative Commons: Attribution (CC BY)

GordonN2021UrineFinal published version, 973 KBLicence: Creative Commons: Attribution (CC BY)

Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification
Ward, D., Gordon, N., Boucher, R., Pirrie, S., Baxter, L., Ott, S., Silcock, L., Whalley, C., Stockton, J., Beggs, A., Griffiths, M., Abbotts, B., Ijakipour, H., Latheef, F., Robinson, R., White, A., James, N., Zeegers, M., Cheng, K. & Bryan, R., Sept 2019, In: BJU international. 124, 3, p. 532-544 13 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
17 Citations (Scopus)

368 Downloads (Pure)

Amplicon deep sequencing of urinary DNA for the early detection of recurrence following chemo-radiotherapy for muscle-invasive bladder cancer (AmpseqUr-RT)
Bryan, R. (Principal Investigator) & Ward, D. (Co-Investigator)
Cancer Research UK
1/02/19 → 31/10/20
Project: Research
Amplicon deep sequencing of Urinary DNA for the detection of bladder cancer: AmpseqUr
Ward, D. (Co-Investigator) & Bryan, R. (Principal Investigator)
Cancer Research UK
1/02/17 → 30/05/21
Project: Research
Bladder Cancer Prognosis Programme
Bryan, R. (Principal Investigator)
NIHR
1/05/10 → 31/07/13
Project: Other Government Departments

Cite this

Gordon, N. S., Baxter, L. A., Goel, A., Arnold, R., Kaur, B., Liu, W., Pirrie, S. J., Hussain, S., Viney, R., Ford, D., Zarkar, A., Wood, M. A., Mitin, T., Thompson, R. F., James, N. D., Ward, D. G., & Bryan, R. T. (2022). Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study. BJU International , 129(1), 32-34. https://doi.org/10.1111/bju.15589

@article{8b748f71f8b54fa7a7b89c5a0f33ceff,

title = "Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study",

keywords = "Urology, Cetuximab/administration \& dosage, Liquid Biopsy, Neoplasm Invasiveness, Humans, Treatment Outcome, Tumor Suppressor Protein p53/genetics, Neoplasm Recurrence, Local/genetics, Chemoradiotherapy, Sequence Analysis, DNA, Mitomycin/administration \& dosage, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Pilot Projects, Urinary Bladder Neoplasms/genetics, DNA, Neoplasm/analysis, Fluorouracil/administration \& dosage, Muscle, Smooth/pathology, Mutation, Receptor, Fibroblast Growth Factor, Type 3/genetics, Clinical Trials, Phase I as Topic, Biomarkers, Tumor/urine, Clinical Trials, Phase II as Topic, Telomerase/genetics",

author = "Gordon, \{Naheema S\} and Baxter, \{Laura A\} and Anshita Goel and Roland Arnold and Baljit Kaur and Wenyu Liu and Pirrie, \{Sarah J\} and Syed Hussain and Richard Viney and Daniel Ford and Anjali Zarkar and Wood, \{Mary A\} and Timur Mitin and Thompson, \{Reid F\} and James, \{Nicholas D\} and Ward, \{Douglas G\} and Bryan, \{Richard T\}",

note = "Funding Information: The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee – CRUK‐OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd. Funding Information: Timur Mitin: UpToDate, Inc (royalties for chapter authorship), Novocure (study grant and advisory board), AstraZeneca (advisory board). Richard T. Bryan: Olympus Medical Systems (advisory board), Janssen (advisory board), UroGen Pharma (research grant), QED Therapeutics (research grant), Nonacus Limited (advisory board). Douglas G. Ward: Nonacus Limited (advisory board). Funding Information: The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee ? CRUK-OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd. The authors thank Katie Marquis, Florence Pethick and Giorgio Pea from Thermo Fisher UK, Nonacus Limited, and West Midlands Regional Genetics Laboratory. The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee ? CRUK-OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd. Funding Information: The authors thank Katie Marquis, Florence Pethick and Giorgio Pea from Thermo Fisher UK, Nonacus Limited, and West Midlands Regional Genetics Laboratory. The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee – CRUK‐OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd.",

year = "2022",

month = jan,

day = "1",

doi = "10.1111/bju.15589",

language = "English",

volume = "129",

pages = "32--34",

journal = "BJU International ",

issn = "1464-4096",

publisher = "Wiley",

number = "1",

}

Gordon, NS, Baxter, LA, Goel, A , Arnold, R, Kaur, B, Liu, W, Pirrie, SJ, Hussain, S, Viney, R, Ford, D, Zarkar, A, Wood, MA, Mitin, T, Thompson, RF, James, ND, Ward, DG & Bryan, RT 2022, 'Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study', BJU International , vol. 129, no. 1, pp. 32-34. https://doi.org/10.1111/bju.15589

TY - JOUR

T1 - Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer

T2 - a pilot study

AU - Gordon, Naheema S

AU - Baxter, Laura A

AU - Goel, Anshita

AU - Arnold, Roland

AU - Kaur, Baljit

AU - Liu, Wenyu

AU - Pirrie, Sarah J

AU - Hussain, Syed

AU - Viney, Richard

AU - Ford, Daniel

AU - Zarkar, Anjali

AU - Wood, Mary A

AU - Mitin, Timur

AU - Thompson, Reid F

AU - James, Nicholas D

AU - Ward, Douglas G

AU - Bryan, Richard T

N1 - Funding Information: The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee – CRUK‐OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd. Funding Information: Timur Mitin: UpToDate, Inc (royalties for chapter authorship), Novocure (study grant and advisory board), AstraZeneca (advisory board). Richard T. Bryan: Olympus Medical Systems (advisory board), Janssen (advisory board), UroGen Pharma (research grant), QED Therapeutics (research grant), Nonacus Limited (advisory board). Douglas G. Ward: Nonacus Limited (advisory board). Funding Information: The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee ? CRUK-OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd. The authors thank Katie Marquis, Florence Pethick and Giorgio Pea from Thermo Fisher UK, Nonacus Limited, and West Midlands Regional Genetics Laboratory. The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee ? CRUK-OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd. Funding Information: The authors thank Katie Marquis, Florence Pethick and Giorgio Pea from Thermo Fisher UK, Nonacus Limited, and West Midlands Regional Genetics Laboratory. The liquid biopsy work was funded by a Cancer Research UK Early Detection Committee – CRUK‐OHSU Spark Award (C16909/A27035). The TUXEDO trial was funded by Cancer Research UK (CRUK/09/021) and cetuximab was supplied by Merck Serono Ltd.

PY - 2022/1/1

Y1 - 2022/1/1

KW - Urology

KW - Cetuximab/administration & dosage

KW - Liquid Biopsy

KW - Neoplasm Invasiveness

KW - Humans

KW - Treatment Outcome

KW - Tumor Suppressor Protein p53/genetics

KW - Neoplasm Recurrence, Local/genetics

KW - Chemoradiotherapy

KW - Sequence Analysis, DNA

KW - Mitomycin/administration & dosage

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Pilot Projects

KW - Urinary Bladder Neoplasms/genetics

KW - DNA, Neoplasm/analysis

KW - Fluorouracil/administration & dosage

KW - Muscle, Smooth/pathology

KW - Mutation

KW - Receptor, Fibroblast Growth Factor, Type 3/genetics

KW - Clinical Trials, Phase I as Topic

KW - Biomarkers, Tumor/urine

KW - Clinical Trials, Phase II as Topic

KW - Telomerase/genetics

UR - https://www.scopus.com/pages/publications/85115144230

U2 - 10.1111/bju.15589

DO - 10.1111/bju.15589

M3 - Article

C2 - 34491610

SN - 1464-4096

VL - 129

SP - 32

EP - 34

JO - BJU International

JF - BJU International

IS - 1

ER -

Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study

Bibliographical note

UN SDGs

Keywords

Access to Document

Research output

Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification

Projects

Amplicon deep sequencing of urinary DNA for the early detection of recurrence following chemo-radiotherapy for muscle-invasive bladder cancer (AmpseqUr-RT)

Amplicon deep sequencing of Urinary DNA for the detection of bladder cancer: AmpseqUr

Bladder Cancer Prognosis Programme

Cite this